Bryostatin analogues - Aphios Corporation
Alternative Names: APH-0703; APH-1104; Bryosomes; Bryostatin 1-containing phospholipid nanosomes (Bryosomes™) - Aphios; Nanoencapsulated APH 0703Latest Information Update: 28 Jan 2024
At a glance
- Originator Aphios Corporation
- Developer Aphios Corporation; Louisiana State University; University Hospital Muenster
- Class Antidementias; Antineoplastics; Lactones; Macrocyclic compounds; Nootropics
- Mechanism of Action Amyloid beta-protein inhibitors; Protein kinase C stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Alzheimer's disease; Cognition disorders
- No development reported Down syndrome; Reperfusion injury
- Discontinued Oesophageal cancer
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Down syndrome in USA (PO)
- 28 Apr 2023 No recent reports of development identified for preclinical development in Reperfusion-injury in Germany
- 28 Apr 2023 No recent reports of development identified for preclinical development in Reperfusion-injury in USA